Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The Lancet Oncology - Tập 16 Số 2 - Trang 141-151 - 2015
James Chih‐Hsin Yang1, Yi‐Long Wu2, Martin Schüler3, Martin Sebastian4, Sanjay Popat5, Nobuyuki Yamamoto6, Caicun Zhou7, Cheng-Ping Hu8, Kenneth J. O’Byrne9, Jifeng Feng10, Shun Lü11, Yunchao Huang12, Sarayut Lucien Geater13, Kye Young Lee14, Chun-Ming Tsai15, В. А. Горбунова16, Vera Hirsh17, Jaafar Bennouna18, С. В. Орлов19, Tony Mok20, Michael Boyer21, Wu‐Chou Su22, Ki Hyeong Lee23, Terufumi Kato24, Dan Massey25, Mehdi Shahidi25, Victoria Zazulina25, Lecia V. Sequist26
1National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan.
2Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
3West German Cancer Center, University Hospital Essen, University Duisburg Essen, Essen, Germany
4Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, and University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
5Royal Marsden Hospital, London, UK
6Wakayama Medical University, Wakayama, Japan
7Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
8Xiangya Hospital, Central South University, Changsha, China
9Princess Alexandra Hospital and Queensland University of Technology, Australia
10Jiangsu Province Cancer Hospital, Nanjing, Jiangsu, China
11Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
12Yunnan Tumor Hospital (The Third Affiliated Hospital of Kunming Medical University), Kunming, Yunnan Province, China
13Prince of Songkla University, Songkhla, Thailand
14Department of Internal Medicine, Konkuk University Medical Center, Seoul, South Korea
15Taipei Veterans General Hospital, Taipei, Taiwan
16FSBI “N N Blokhin Russian Cancer Research Centre”, Russian Academy of Medical Sciences, Moscow, Russia
17McGill University Montreal, Canada
18Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France
19Pavlov State Medical University, St.Petersburg, Russia#TAB#
20State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China
21Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
22National Cheng-Kung University Hospital, Tainan, Taiwan
23Chungbuk National University Hospital, Cheongju, South Korea
24Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
25Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK
26Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Mok, 2013, Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference?, J Clin Oncol, 31, 1081, 10.1200/JCO.2012.43.0652

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X

Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X

Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X

Wu, 2013, First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): Interim analyses from the Phase 3, open-label, ENSURE study, J Thorac Oncol, 8, S603

Han, 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, J Clin Oncol, 30, 1122, 10.1200/JCO.2011.36.8456

Fukuoka, 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, 29, 2866, 10.1200/JCO.2010.33.4235

Yang, 2011, Efficacy outcomes in first-line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene-copy number score and by most common EGFR mutation subtypes—exploratory data from IPASS, Eur J Cancer, 47, S633, 10.1016/S0959-8049(11)72444-3

Inoue, 2013, Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002), Ann Oncol, 24, 54, 10.1093/annonc/mds214

Mitsudomi, 2012, Proc Am Soc Clin Oncol, 30, 7521, 10.1200/jco.2012.30.15_suppl.7521

Zhou, 2012, Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 30, 7520, 10.1200/jco.2012.30.15_suppl.7520

Yoshioka, 2014, Proc Am Soc Clin Oncol, 32, 8117, 10.1200/jco.2014.32.15_suppl.8117

Lee, 2013, Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis, J Natl Cancer Inst, 105, 595, 10.1093/jnci/djt072

Yang, 2012, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial, Lancet Oncol, 13, 539, 10.1016/S1470-2045(12)70086-4

Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3327, 10.1200/JCO.2012.44.2806

Wu, 2014, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, 15, 213, 10.1016/S1470-2045(13)70604-1

Yang, 2013, Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3342, 10.1200/JCO.2012.46.1764

Collett, 2003

Shuster, 1991, Median follow-up in clinical trials, J Clin Oncol, 9, 191, 10.1200/JCO.1991.9.1.191

Rosell, 2009, Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 361, 958, 10.1056/NEJMoa0904554

Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer, 7, 169, 10.1038/nrc2088

Jackman, 2006, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib, Clin Cancer Res, 12, 3908, 10.1158/1078-0432.CCR-06-0462

Jackman, 2009, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials, Clin Cancer Res, 15, 5267, 10.1158/1078-0432.CCR-09-0888

Riely, 2006, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res, 12, 839, 10.1158/1078-0432.CCR-05-1846

Ding, 2013, Exon 19 deletions, smoking history and gender as additional predictive factors for treatment benefit with EGFR tyrosine kinase inhibitors in patients harbouring activating EGFR mutations: a meta-analysis of 1432 patients in six randomised trials, J Thorac Oncol, 8

Okabe, 2007, Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification, Cancer Res, 67, 2046, 10.1158/0008-5472.CAN-06-3339

Zhu, 2008, Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals, Cancer Lett, 265, 307, 10.1016/j.canlet.2008.02.064

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 16 Số 2

141-151

Thông tin tác giả